- Receptos (RCPT +22.7%) soars after saying the DMC for its Phase 2/3 trial of RPC1063 in RMS has recommended both the continuation of the Phase 2 portion of the study and the initiation of the Phase 3 component.
- The company says data from an interim analysis "support the RPC1063 differentiation profile and [is] consistent with data from prior RPC1063 studies."
- Expect top-line data from Phase 2 in mid-2014. (PR)
From other sites
at CNBC.com (Feb 26, 2015)
Video at CNBC.com (Feb 26, 2015)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 15, 2015)
at CNBC.com (Jan 6, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs